Abstract:Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC There have been a lot studies focusing on EGFR mutation analysis in the patients of lung cancer especially in the patients with adenocarcinoma, for EGFR mutation has shown helpful in patient prognosis and therapeutic selection. Erlotinib and Gefitinib are playing increasing role in late stage adenocarcinoma of lung although it has not been listed as a first line treatment for advanced patients of Asian ethnic yet. However, the fact of a better respond rate to Erlotinib and Gefitinib and longer survival related to the mutant status of EGFR gene among Asian patients is encouraging the use for routine test of this gene in clinical service for lung cancer patients. Ninety two Chinese cancer patients were included into the study, from which 60 were lung cancer. The other cases were 11 supraclavicular lymph node biopsies and 21 tumor masses of different sites with differentiation diagnosis needed. EGFR mutation analysis was performed in DNA extracted from tumor tissue or biopsy samples. Overall mutation rate of EGFR was 42.39% (39/92) in whole patient group. The mutation rate in lung cancer was 46.67% (28/60) whereas it turned to 58.14% (25/43) when only looking at adenocarcinoma (56.10%, 23/41) and adenosquamous carcinoma (100%, 2/2). No mutation was found in squamous carcinoma, large cell carcinoma and poorly differentiated carcinoma. EGFR mutation analysis in the samples from Endobronchila Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for mediastinal masses revealed an EGFR mutation rate of 42.86% (3/7), mimicking the mutation rate of lung cancer in our study. Forty eight percent of the EGFR mutation was located in exon 19 and 36% of the mutation in exon 21. Mutation of exon 19 seemed to be lower in the patient group older (35.71%, 5/14) than 58 year old (median age) than that in the patient group younger than 58 year old (58.82%, 10/17) (P=0.0581). In opposition, mutation rate of exon 21 appeared higher in the older group (64.29%, 9/14) than that in the younger patient group (23.53%, 4/17) (P=0.0800). The mutations in male patients were mainly located in exon 19 (71.43%, 10/14). And the mutation rate of exon 19 and 21 in female patients showed very close (43.47%, 10/23 for exon 19 and 47.83%, 11/23 for exon 21). Mutation rate of exon 20 was generally low but showed a higher rate in younger and female patients (17.65% and 13.04%). Mutation of supraclavicular lymph node was quite high (36.37%, 4/11) while mutation rate from variant site was low (20.00%, 4/20). One adenocarcinoma located in uterus muscle layer was demonstrated to possess an exon 19 mutation. All follow up analysis is in process. In conclusion, EGFR mutation analysis is a useful tool in defining patients suitable for EGFR TKI treatment as well as helpful in differentiation diagnosis in metastasis lesion. Mutation analysis in the samples derived from EBUS-TBNA is especially of important with clinical value. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4669.

PUB079 EGFR and BRAF Mutation Detection in FFPE Samples of Lung Adenocarcinoma

Detection of EGFR and BRAF Mutations by Competitive Allele-Specific TaqMan Polymerase Chain Reaction in Lung Adenocarcinoma.

The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Targeted Next-Generation Sequencing of 491 Lung Cancers in Clinical Practice: Implications for Future Detection Strategy and Targeted Therapy

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

P1.02-043 A Comparison of Consistency of Detecting BRAF Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients

The Mutation Profile of EGFR in Resectable Chinese Lung Cancer Patients.

Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma

Abstract 4669: EGFR Gene Mutation Analysis in Chinese Lung Cancer Patients: Value for Differentiation Diagnostics and Therapeutics

Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology

Comprehensive Analysis of NGS and ARMS-PCR for Detecting EGFR Mutations Based on 4467 Cases of NSCLC Patients

P3.02b-011 Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Patients with Non-Small Cell Lung Carcinoma

Analysis of epidermal growth factor receptor gene mutations in 406 small biopsy samples of lung cancer

Non-invasive and Quantitative Analysis for EGFR T790M Mutation in the Patients with Advanced Non-Small Cell Lung Cancer Received EGFR-TKI Therapy.

Ctdna Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non-Small Cell Lung Cancer in Real-World Setting

A Simple and Rapid Method for Detecting Major Mutations of Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer

Sensitive Genotyping Of Mutations In The Egfr Gene From Nsclc Patients Using Pcr-Goldmag Lateral Flow Device